Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $815871.0.

  • China Pharma Holdings' Cost of Revenue fell 4963.14% to $815871.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 3964.72%. This contributed to the annual value of $6.5 million for FY2024, which is 1066.6% down from last year.
  • China Pharma Holdings' Cost of Revenue amounted to $815871.0 in Q3 2025, which was down 4963.14% from $1.1 million recorded in Q2 2025.
  • China Pharma Holdings' Cost of Revenue's 5-year high stood at $2.9 million during Q4 2022, with a 5-year trough of $815871.0 in Q3 2025.
  • In the last 5 years, China Pharma Holdings' Cost of Revenue had a median value of $1.8 million in 2022 and averaged $1.8 million.
  • As far as peak fluctuations go, China Pharma Holdings' Cost of Revenue soared by 5590.95% in 2024, and later crashed by 4963.14% in 2025.
  • Over the past 5 years, China Pharma Holdings' Cost of Revenue (Quarter) stood at $2.6 million in 2021, then grew by 11.24% to $2.9 million in 2022, then decreased by 22.56% to $2.2 million in 2023, then plummeted by 41.92% to $1.3 million in 2024, then crashed by 36.98% to $815871.0 in 2025.
  • Its last three reported values are $815871.0 in Q3 2025, $1.1 million for Q2 2025, and $1.3 million during Q1 2025.